AstraZeneca files Zactima for NSCLC in US and EU
This article was originally published in Scrip
Executive Summary
AstraZeneca has filed its oral targeted anticancer Zactima (vandetanib) with both the US FDA and the EMEA, for use in combination with chemotherapy as a second-line treatment for advanced non–small cell lung cancer (NSCLC).